Literature DB >> 12067239

Focal neurometabolic alterations in mice deficient for succinate semialdehyde dehydrogenase.

K M Gibson1, D S M Schor, M Gupta, W S Guerand, H Senephansiri, T G Burlingame, H Bartels, B M Hogema, T Bottiglieri, W Froestl, O C Snead, M Grompe, C Jakobs.   

Abstract

Metabolite profiling in succinate semialdehyde dehydrogenase (SSADH; Aldh5a1-/-) deficient mice previously revealed elevated gamma-hydroxybutyrate (GHB) and total GABA in urine and total brain and liver extracts. In this study, we extend our metabolic characterization of these mutant mice by documenting elevated GHB and total GABA in homogenates of mutant kidney, pancreas and heart. We quantified beta-alanine (a GABA homolog and putative neurotransmitter) to address its potential role in pathophysiology. We found normal levels of beta-alanine in urine and total homogenates of mutant brain, heart and pancreas, but elevated concentrations in mutant kidney and liver extracts. Amino acid analysis in mutant total brain homogenates revealed no abnormalities except for significantly decreased glutamine, which was normal in mutant liver and kidney extracts. Regional amino acid analysis (frontal cortex, parietal cortex, hippocampus and cerebellum) in mutant mice confirmed glutamine results. Glutamine synthetase protein and mRNA levels in homogenates of mutant mouse brain were normal. We profiled organic acid patterns in mutant brain homogenates to assess brain oxidative metabolism and found normal concentrations of Kreb's cycle intermediates but increased 4,5-dihydroxyhexanoic acid (a postulated derivative of succinic semialdehyde) levels. We conclude that SSADH-deficient mice represent a valid metabolic model of human SSADH deficiency, manifesting focal neurometabolic abnormalities which could provide key insights into pathophysiologic mechanisms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12067239     DOI: 10.1046/j.1471-4159.2002.00784.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  18 in total

Review 1.  Succinic semialdehyde dehydrogenase: biochemical-molecular-clinical disease mechanisms, redox regulation, and functional significance.

Authors:  Kyung-Jin Kim; Phillip L Pearl; Kimmo Jensen; O Carter Snead; Patrizia Malaspina; Cornelis Jakobs; K Michael Gibson
Journal:  Antioxid Redox Signal       Date:  2011-04-10       Impact factor: 8.401

Review 2.  Thirty years beyond discovery--clinical trials in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism.

Authors:  Kara R Vogel; Phillip L Pearl; William H Theodore; Robert C McCarter; Cornelis Jakobs; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2012-06-28       Impact factor: 4.982

3.  Epilepsy in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism.

Authors:  Phillip L Pearl; Lovy Shukla; William H Theodore; Cornelis Jakobs; K Michael Gibson
Journal:  Brain Dev       Date:  2011-06-12       Impact factor: 1.961

4.  Therapeutic relevance of mTOR inhibition in murine succinate semialdehyde dehydrogenase deficiency (SSADHD), a disorder of GABA metabolism.

Authors:  K R Vogel; G R Ainslie; E E W Jansen; G S Salomons; K M Gibson
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2016-10-17       Impact factor: 5.187

5.  Expression profiling reveals multiple myelin alterations in murine succinate semialdehyde dehydrogenase deficiency.

Authors:  Elizabeth A Donarum; Dietrich A Stephan; Kay Larkin; Eric J Murphy; Maneesh Gupta; Henry Senephansiri; Robert C Switzer; Phillip L Pearl; O Carter Snead; C Jakobs; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2006-02       Impact factor: 4.982

6.  Therapeutic concepts in succinate semialdehyde dehydrogenase (SSADH; ALDH5a1) deficiency (gamma-hydroxybutyric aciduria). Hypotheses evolved from 25 years of patient evaluation, studies in Aldh5a1-/- mice and characterization of gamma-hydroxybutyric acid pharmacology.

Authors:  I Knerr; P L Pearl; T Bottiglieri; O Carter Snead; C Jakobs; K M Gibson
Journal:  J Inherit Metab Dis       Date:  2007-04-24       Impact factor: 4.982

7.  Neuropsychiatric morbidity in adolescent and adult succinic semialdehyde dehydrogenase deficiency patients.

Authors:  Ina Knerr; K Michael Gibson; Cornelis Jakobs; Phillip L Pearl
Journal:  CNS Spectr       Date:  2008-07       Impact factor: 3.790

8.  Evidence for oxidative stress in tissues derived from succinate semialdehyde dehydrogenase-deficient mice.

Authors:  A Latini; K Scussiato; G Leipnitz; K M Gibson; M Wajner
Journal:  J Inherit Metab Dis       Date:  2007-09-21       Impact factor: 4.982

9.  Post-mortem tissue analyses in a patient with succinic semialdehyde dehydrogenase deficiency (SSADHD). I. Metabolomic outcomes.

Authors:  Trevor Kirby; Dana C Walters; Madalyn Brown; Erwin Jansen; Gajja S Salomons; Coleman Turgeon; Piero Rinaldo; Erland Arning; Paula Ashcraft; Teodoro Bottiglieri; Jean-Baptiste Roullet; K Michael Gibson
Journal:  Metab Brain Dis       Date:  2020-03-14       Impact factor: 3.584

10.  Neurotransmitter alterations in embryonic succinate semialdehyde dehydrogenase (SSADH) deficiency suggest a heightened excitatory state during development.

Authors:  Erwin E W Jansen; Eduard Struys; Cornelis Jakobs; Elizabeth Hager; O Carter Snead; K Michael Gibson
Journal:  BMC Dev Biol       Date:  2008-11-28       Impact factor: 1.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.